Biggest News Aggregation in the World
📰 Rom News

Page 448 - Rom News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Rom. Real-time updates on events, politics, business and more.

Bristol Myers Squibb to Present First Results at ASCO and EHA from Phase 3 COMMANDS Study of Reblozyl® (luspatercept-aamt) in First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)

Results from Phase 3 COMMANDS study, selected for ASCO’s official press program, show nearly twice as many patients treated with Reblozyl achieved superior transfusion independence with... | May 25, 2023
United States Maedica Bucur Noah Berkowitz Guillermo Garcia Manero Bristol Myers Squibb Origar Beta

Deciphera Pharmaceuticals to Present Data from INTRIGUE Phase 3 Study of QINLOCK® (ripretinib) and Trial-in-Progress Poster for INSIGHT Pivotal Phase 3 Study of QINLOCK® at the 2023 American Society of Clinical Oncology Annual Meeting

– Company Presents Poster on Overall Survival and Long-Term Safety Results from INTRIGUE Study; Second Poster Presents Analysis from INTRIGUE Patients without Detectable ctDNA at Baseline... | May 25, 2023
Hong Kong United States United Kingdom New Zealand West German Sebastian Bauer

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Adaptimmune Therapeutics PLC: Adaptimmune Announces 70% of People with Advanced Synovial Sarcoma Who Respond to Afami-cel are Alive Two Years Post-Treatment; Data from Cohort 1 of SPEARHEAD-1 to be Presented at ASCO

Approximately 39% of patients had clinical responses after a single dose of afami-cel in Cohort 1 of the pivotal SPEARHEAD-1 trial and the median duration of response was ~12 months (CTOS 2022)Median
Gewinn Nur Dana Lynch Dennis Williams Julip Miller John Charlson College Of Wisconsin

Bristol Myers Squibb to Present First Results at ASCO and EHA from Phase 3 COMMANDS Study of Reblozyl (luspatercept-aamt) in First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)

Results from Phase 3 COMMANDS study, selected for ASCO's official press program, show nearly twice as many patients treated with Reblozyl achieved superior transfusion independence with concurrent
United States Bristol Myers Squibb Noah Berkowitz Origar Beta Maedica Bucur Gewinn Nur

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science